Tocagen Inc (TOCA)

[gr8db8]

AANS: 2120. Immune Monitoring of High Grade Glioma Patients in a Phase 1 Clinical Trial of Toca 511 and Toca FC

Conclusions
? Human immune monitoring results support an immunologic mechanism
of action for Toca 511 & Toca FC treatment. Preliminary analyses
identified potential immune signatures that may reflect patient outcomes
and should be explored further.
• Tumor infiltrating NK cells, M0 macrophages and activated CD4+ memory T-
cells may predict patient outcomes including objective response and survival
• Peripheral serum cytokine modulations during Toca 511 & Toca FC treatment
could be useful to monitor patient responses and indicate long term survival
• Post-treatment expansion of PD-1+ and Ki-67+ T-cell subsets in the peripheral
blood of responding patients suggests potential immune activation related to
therapeutic benefit
? This clinical research helps support and clarify the immune-related
mechanism of action for Toca 511 & Toca FC previously observed in non-
clinical models
? Potential immunological associations with patient outcomes will be
evaluated in the ongoing randomized Phase 3 trial in patients with rHGG
(NCT02414165), Toca 5

https://360.aans.org/AppSearch/Eposter?eventid=48888&itemid=EPOSTER&propid=46117